Therefore, French companies which have outsourced research and development to RecipharmCobra will be able to benefit from the research and development tax credit (Le Crédit d’Impôt Recherche (CIR)).
This approval is granted for the years: 2010 and 2011.
“The ongoing approval means that our customers in France can continue to take advantage of the tax breaks the French Government has made available,” said Simon Saxby, VP. “RecipharmCobra is already an active player in the French market and we will continue improve our services more than ever during these economically testing times.”
For further information: http://www.enseignementsup-recherche.gouv.fr/cid20358/le-credit-d-impot-recherche-cir.html
About the research and development tax credit (Le Crédit d’Impôt Recherche (CIR))
CIR is a fiscal support for companies involved in R&D expenditure. The CIR is deducted from the tax to be paid or else it is refunded at the end of the third year. However, it is immediately paid to young companies under certain conditions. Companies that can neither deduct the tax credit nor obtain a refund can ask banks for loans on the basis of their research tax credit. The CIR is based on the claimed volume of R&D expenditures. It is equal to 30 % of R&D expenditures up to EUR 100 million; beyond this threshold, the rate comes down to 5 %. For companies entering the scheme for the first time, the applicable rate is 50 % the first year, and 40 % the second year.
About RecipharmCobra Biologics
RecipharmCobra Biologics has a proven track record in the development and manufacture of monoclonal antibodies, recombinant therapeutic proteins, viruses and DNA as well as cell based vaccines and therapies for clinical trials and regulatory approvals. RecipharmCobra Biologics has two GMP approved production facilities, from which a comprehensive service is provided; including cell line development, process and analytical development, GMP manufacture, coordination of formulation and fill/finish activities, and release to clinic.
RecipharmCobra is the specialist biologics division of Recipharm AB. www.recipharmcobrabio.com
About Recipharm
Recipharm AB is a leading contract development and manufacturing organisation based in Sweden with 2,000 employees. The company operates 12 development and manufacturing facilities in Sweden, France, the UK, Spain and Germany and is headquartered near Stockholm. We supply the global pharmaceuticals market with hundreds of different products in most dosage forms, including solid dose, granulates, powders, sterile liquids and lyophilisates, semisolids, beta-lactams, hormones, and inhalers.
www.recipharm.com
Contact Simon Saxby Vice President of Biologics, RecipharmCobra Biologics +44 (0) 1782 714 181 For media enquiries, pleased contact Tristan Jervis or Alex Heeley +44 (0) 207 861 3019. E-mail: t.jervis@defacto.com
